AC Immune (NASDAQ:ACIU) Now Covered by Analysts at HC Wainwright

Research analysts at HC Wainwright began coverage on shares of AC Immune (NASDAQ:ACIU) in a research note issued on Thursday, Zacks reports. The firm set a “strong-buy” rating on the stock. HC Wainwright also issued estimates for AC Immune’s Q1 2027 earnings at $0.06 EPS, Q2 2027 earnings at $0.06 EPS, Q3 2027 earnings at $0.14 EPS and Q4 2027 earnings at $0.17 EPS.

A number of other brokerages have also recently commented on ACIU. BTIG Research reiterated a “buy” rating and issued a $8.00 price target on shares of AC Immune in a research note on Wednesday, September 23rd. Zacks Research lowered AC Immune from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 28th. Finally, Weiss Ratings raised AC Immune from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, AC Immune has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

AC Immune Price Performance

Shares of NASDAQ:ACIU opened at $2.11 on Thursday. The firm has a 50 day simple moving average of $2.55 and a 200 day simple moving average of $2.70. AC Immune has a one year low of $2.02 and a one year high of $3.90.

AC Immune (NASDAQ:ACIU) last posted its earnings results on Wednesday, November 4th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The firm had revenue of $3.88 million for the quarter, compared to analysts’ expectations of $1.62 million. AC Immune had a negative net margin of 181.38% and a negative return on equity of 97.79%. Sell-side analysts forecast that AC Immune will post -0.60 EPS for the current fiscal year.

Institutional Investors Weigh In On AC Immune

A number of institutional investors have recently added to or reduced their stakes in ACIU. Arrowstreet Capital Limited Partnership increased its position in AC Immune by 8.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after acquiring an additional 30,035 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after acquiring an additional 176,701 shares during the last quarter. Finally, AXQ Capital LP acquired a new position in shares of AC Immune during the second quarter worth $25,000. 51.36% of the stock is owned by institutional investors.

AC Immune Company Profile

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.